Metabolic reprogramming and epigenetic modifications are hallmarks of cancer cells. In
cancer cells, metabolic pathway activity varies during tumorigenesis and cancer …

The genomic simplicity of differentiated cancers derived from thyroid follicular cells offers
unique insights into how oncogenic drivers impact tumour phenotype. Essentially, the main …

Background The development of systemic treatment options leveraging the molecular
landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary …

MAPK signaling inhibitor (MAPKi) therapies show limited efficacy for advanced thyroid
cancers despite constitutive activation of the signaling correlates with disease recurrence …

Tumours can arise from thyroid follicular cells if they acquire driver mutations that
constitutively activate the MAPK signalling pathway. In addition, a limited set of additional …

The impact of BRAF mutations on the clinical outcomes of PTC remains debatable. In ATCs,
in turn, BRAF mutations identify patients eligible for targeted therapy, which is now …

Background: Oncogenic activation of mitogen-activated protein kinase (MAPK) signaling is
associated with radioiodine refractory (RAIR) thyroid cancer. Preclinical models suggest that …

PURPOSE Selumetinib can increase radioactive iodine (RAI) avidity in RAI-refractory
tumors. We investigated whether selumetinib plus adjuvant RAI improves complete …

Purpose: The determinants of response or resistance to radioiodine (RAI) are unknown. We
aimed to identify genomic and transcriptomic factors associated with structural responses to …

Background: Very little was known about the molecular pathogenesis of thyroid cancer until
the late 1980s. As part of the Centennial celebration of the American Thyroid Association …